Media inquiries only, please contact Andrea Hofelich via email or phone, 202-827-2078.
The National Pharmaceutical Council and Discern Health today released a white paper analyzing the gaps in accountable care quality measure sets for cancer, which can lead to missed opportunities to spot problems or improve care.
(Washington, D.C., March 28, 2017) — The National Pharmaceutical Council (NPC) today announced that Ipsen Biopharmaceuticals, Inc. has joined the health policy research organization as its newest member.
New Study Probes Stakeholder Attitudes on Ethics and Fairness of Cost-Sharing to Steer Appropriate Medication Use ( )
Payers, patients, employers and researchers identified five principles for when it is less acceptable for patients with the same condition to have different costs, according to a new study published in the Journal of Managed Care & Specialty Pharmacy.
The National Pharmaceutical Council (NPC) commented on the Institute of Clinical and Economic Review’s (ICER) updated value assessment framework, which was released today.
Gaps in the quality measures used by accountable care programs to assess cancer care may obscure problems in care delivery and lead to missed opportunities for improvement of patient outcomes, according to a new study from NPC, Discern Health, the Duke-Margolis Center for Health Policy, and the American Society of Clinical Oncology, published in the Journal of Managed Care & Specialty Pharmacy.
Amgen’s Dr. Joshua Ofman Elected Chairman of National Pharmaceutical Council’s Board of Directors ( )
The National Pharmaceutical Council (NPC) Board of Directors today elected Joshua Ofman, MD, MSHS, Senior Vice President of Global Value, Access & Policy, Amgen, as its 2016-2017 Chairman. Dr. Ofman has served on NPC’s Board since 2012, most recently as Vice Chairman.